Cargando…
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512075/ https://www.ncbi.nlm.nih.gov/pubmed/37744366 http://dx.doi.org/10.3389/fimmu.2023.1269596 |
| _version_ | 1785108283673018368 |
|---|---|
| author | Zeng, Zhimin Qian, Xiaoying Liu, Fanrong Wang, Yong Yuan, Yong Fang, Chen Zhang, Xinwei Yuan, Shangkun Chen, Renfang Yu, Biao Wang, Tong Yin, Yan Li, Yong Liu, Anwen |
| author_facet | Zeng, Zhimin Qian, Xiaoying Liu, Fanrong Wang, Yong Yuan, Yong Fang, Chen Zhang, Xinwei Yuan, Shangkun Chen, Renfang Yu, Biao Wang, Tong Yin, Yan Li, Yong Liu, Anwen |
| author_sort | Zeng, Zhimin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10512075 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105120752023-09-22 Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma Zeng, Zhimin Qian, Xiaoying Liu, Fanrong Wang, Yong Yuan, Yong Fang, Chen Zhang, Xinwei Yuan, Shangkun Chen, Renfang Yu, Biao Wang, Tong Yin, Yan Li, Yong Liu, Anwen Front Immunol Immunology Frontiers Media S.A. 2023-09-06 /pmc/articles/PMC10512075/ /pubmed/37744366 http://dx.doi.org/10.3389/fimmu.2023.1269596 Text en Copyright © 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Zeng, Zhimin Qian, Xiaoying Liu, Fanrong Wang, Yong Yuan, Yong Fang, Chen Zhang, Xinwei Yuan, Shangkun Chen, Renfang Yu, Biao Wang, Tong Yin, Yan Li, Yong Liu, Anwen Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title | Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title_full | Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title_fullStr | Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title_full_unstemmed | Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title_short | Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| title_sort | corrigendum: the efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512075/ https://www.ncbi.nlm.nih.gov/pubmed/37744366 http://dx.doi.org/10.3389/fimmu.2023.1269596 |
| work_keys_str_mv | AT zengzhimin corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT qianxiaoying corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT liufanrong corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT wangyong corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT yuanyong corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT fangchen corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT zhangxinwei corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT yuanshangkun corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT chenrenfang corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT yubiao corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT wangtong corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT yinyan corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT liyong corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma AT liuanwen corrigendumtheefficacyandsafetyanalysisoffirstlineimmunecheckpointinhibitorsinpulmonarysarcomatoidcarcinoma |